Appendix F Observational results: death from cardiovascular disease

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure
2	Dolecek 1992 1579579	MRFIT	CVD death	CVD mortality	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	EPA+DHA+DPA	Intake
3	Dolecek 1992 1579579	MRFIT	CVD death	CVD mortality	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	EPA+DHA+DPA	Intake
4	Dolecek 1992 1579579	MRFIT	CVD death	CVD mortality	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	EPA+DHA+DPA	Intake
5	Dolecek 1992 1579579	MRFIT	CVD death	CVD mortality	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	EPA+DHA+DPA	Intake
6	Dolecek 1992 1579579	MRFIT	CVD death	CVD mortality	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	EPA+DHA+DPA	Intake
7	Dolecek 1992 1579579	MRFIT	CVD death	all cardiovascular disease	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	EPA+DHA+DPA	Intake
8	Dolecek 1992 1579579	MRFIT	CVD death	CVD mortality	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	EPA+DHA+DPA	Intake
9	Dolecek 1992 1579579	MRFIT	CVD death	CVD mortality	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	EPA+DHA+DPA	Intake
10	Dolecek 1992 1579579	MRFIT	CVD death	CVD mortality	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	EPA+DHA+DPA	Intake
11	Dolecek 1992 1579579	MRFIT	CVD death	CVD mortality	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	EPA+DHA+DPA	Intake
12	Dolecek 1992 1579579	MRFIT	CVD death	CVD mortality	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	EPA+DHA+DPA	Intake
13	Dolecek 1992 1579579	MRFIT	CVD death	all cardiovascular disease	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	EPA+DHA+DPA	Intake
14	Dolecek 1992 1579579	MRFIT	CVD death	CVD mortality	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	ALA	Intake
15	Dolecek 1992 1579579	MRFIT	CVD death	CVD mortality	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	ALA	Intake
16	Dolecek 1992 1579579	MRFIT	CVD death	CVD mortality	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	ALA	Intake
17	Dolecek 1992 1579579	MRFIT	CVD death	CVD mortality	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	ALA	Intake
18	Dolecek 1992 1579579	MRFIT	CVD death	CVD mortality	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	ALA	Intake
19	Dolecek 1992 1579579	MRFIT	CVD death	all cardiovascular disease	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	ALA	Intake
20	Dolecek 1992 1579579	MRFIT	CVD death	CVD mortality	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	ALA	Intake
21	Dolecek 1992 1579579	MRFIT	CVD death	CVD mortality	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	ALA	Intake
22	Dolecek 1992 1579579	MRFIT	CVD death	CVD mortality	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	ALA	Intake
23	Dolecek 1992 1579579	MRFIT	CVD death	CVD mortality	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	ALA	Intake
24	Dolecek 1992 1579579	MRFIT	CVD death	CVD mortality	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	ALA	Intake
25	Dolecek 1992 1579579	MRFIT	CVD death	all cardiovascular disease	Healthy	Men aged 35-57 assigned to the usual care group	Men	232/6258 (3.71)	10.5 y	ALA	Intake
26	Mozaffarian 2013 23546563	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	570/3941 (14.46)	16y	All n-3	Plasma

Row	Study PMID	Supplement	Adjustments	Quantile	n3 units	Quantile low	Quantile median
2	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	Qt1	g/d	nd	0 (mean)
3	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	Qt2	g/d	nd	0.009 (mean)
4	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	Qt3	g/d	nd	0.046 (mean)
5	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	Qt4	g/d	nd	0.153 (mean)
6	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	Qt5	g/d	nd	0.664 (mean)
7	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	All	g/d	nd	nd
8	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	Qt1	% kcal	nd	0 (mean)
9	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	Qt2	% kcal	nd	0.004 (mean)
10	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	Qt3	% kcal	nd	0.019 (mean)
11	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	Qt4	% kcal	nd	0.063 (mean)
12	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	Qt5	% kcal	nd	0.284 (mean)
13	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	All	% kcal	nd	nd
14	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	Qt1	g/d	nd	0.873 (mean)
15	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	Qt2	g/d	nd	1.273 (mean)
16	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	Qt3	g/d	nd	1.577 (mean)
17	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	Qt4	g/d	nd	1.926 (mean)
18	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	Qt5	g/d	nd	2.802 (mean)
19	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	All	g/d	nd	nd
20	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	Qt1	% kcal	nd	0.424 (mean)
21	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	Qt2	% kcal	nd	0.544 (mean)
22	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	Qt3	% kcal	nd	0.63 (mean)
23	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	Qt4	% kcal	nd	0.732 (mean)
24	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	Qt5	% kcal	nd	0.98 (mean)
25	Dolecek 1992 1579579	nd	age ,race, smoking, baseline diastolic blood pressure, high density lipoprotein, low density lipoprotein	All	% kcal	nd	nd
26	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt1	% FA	nd	3.17

Appendix F Observational results: death from cardiovascular disease

Row	Study PMID	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
2	Dolecek 1992 1579579	nd	RR	nd	1307	nd	Reference group				<0.10
3	Dolecek 1992 1579579	nd	RR	nd	1197	nd	1.06	nd	nd		
4	Dolecek 1992 1579579	nd	RR	nd	1251	nd	0.93	nd	nd		
5	Dolecek 1992 1579579	nd	RR	nd	1252	nd	0.93	nd	nd		
6	Dolecek 1992 1579579	nd	RR	nd	1251	nd	0.6	nd	nd		
7	Dolecek 1992 1579579	nd	HR	232	6258	nd	0.38	nd	nd		<0.01
8	Dolecek 1992 1579579	nd	RR	nd	1307	nd	Reference group				<0.10
9	Dolecek 1992 1579579	nd	RR	nd	1196	nd	1.08	nd	nd		
10	Dolecek 1992 1579579	nd	RR	nd	1252	nd	0.81	nd	nd		
11	Dolecek 1992 1579579	nd	RR	nd	1252	nd	1.08	nd	nd		
12	Dolecek 1992 1579579	nd	RR	nd	1251	nd	0.55	nd	nd		
13	Dolecek 1992 1579579	nd	HR	232	6258	nd	0.64	nd	nd		<0.01
14	Dolecek 1992 1579579	nd	RR	nd	1251	nd	Reference group				<0.10
15	Dolecek 1992 1579579	nd	RR	nd	1253	nd	0.93	nd	nd		
16	Dolecek 1992 1579579	nd	RR	nd	1251	nd	0.66	nd	nd		
17	Dolecek 1992 1579579	nd	RR	nd	1251	nd	0.88	nd	nd		
18	Dolecek 1992 1579579	nd	RR	nd	1252	nd	0.61	nd	nd		
19	Dolecek 1992 1579579	nd	HR	232	6258	nd	0.82	nd	nd		<0.10
20	Dolecek 1992 1579579	nd	RR	nd	1251	nd	Reference group				<0.05
21	Dolecek 1992 1579579	nd	RR	nd	1252	nd	0.86	nd	nd		
22	Dolecek 1992 1579579	nd	RR	nd	1252	nd	0.97	nd	nd		
23	Dolecek 1992 1579579	nd	RR	nd	1252	nd	0.66	nd	nd		
24	Dolecek 1992 1579579	nd	RR	nd	1251	nd	0.66	nd	nd		
25	Dolecek 1992 1579579	nd	HR	232	6258	nd	0.46	nd	nd		<0.05
26	Mozaffarian 2013 23546563	nd	HR	nd	nd	nd	Reference group			P trend	<0.001

Appendix F Observational results: death from cardiovascular disease

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure
27	Mozaffarian 2013 23546563	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	570/3941 (14.46)	16y	All n-3	Plasma
28	Mozaffarian 2013 23546563	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	570/3941 (14.46)	16y	All n-3	Plasma
29	Mozaffarian 2013 23546563	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	570/3941 (14.46)	16y	All n-3	Plasma
30	Mozaffarian 2013 23546563	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	570/3941 (14.46)	16y	All n-3	Plasma
31	Mozaffarian 2013 23546563	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	570/3941 (14.46)	16y	DHA	Plasma
32	Mozaffarian 2013 23546563	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	570/3941 (14.46)	16y	DHA	Plasma
33	Mozaffarian 2013 23546563	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	570/3941 (14.46)	16y	DHA	Plasma
34	Mozaffarian 2013 23546563	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	570/3941 (14.46)	16y	DHA	Plasma
35	Mozaffarian 2013 23546563	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	570/3941 (14.46)	16y	DHA	Plasma
36	Mozaffarian 2013 23546563	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	570/3941 (14.46)	16y	EPA	Plasma
37	Mozaffarian 2013 23546563	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	570/3941 (14.46)	16y	EPA	Plasma
38	Mozaffarian 2013 23546563	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	570/3941 (14.46)	16y	EPA	Plasma
39	Mozaffarian 2013 23546563	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	570/3941 (14.46)	16y	EPA	Plasma
40	Mozaffarian 2013 23546563	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	570/3941 (14.46)	16y	EPA	Plasma
41	Fretts 2014 25159901	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	429/2583 (16.61)	12y	ALA	Intake
42	Fretts 2014 25159901	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	429/2583 (16.61)	12y	ALA	Intake
43	Fretts 2014 25159901	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	429/2583 (16.61)	12y	ALA	Intake
44	Fretts 2014 25159901	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	429/2583 (16.61)	12y	ALA	Intake
45	Fretts 2014 25159901	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	429/2583 (16.61)	12y	ALA	Intake

Row	Study PMID	Supplement	Adjustments	Quantile	n3 units	Quantile low	Quantile median
27	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt2	% FA	nd	3.72
28	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt3	% FA	nd	4.21
29	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt4	% FA	nd	4.8
30	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt5	% FA	nd	6.04
31	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt1	% FA	nd	1.95
32	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt2	% FA	nd	2.44
33	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt3	% FA	nd	2.87
34	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt4	% FA	nd	3.36
35	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt5	% FA	nd	4.34
36	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt1	% FA	nd	0.3
37	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt2	% FA	nd	0.41
38	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt3	% FA	nd	0.51
39	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt4	% FA	nd	0.64
40	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt5	% FA	nd	0.92
41	Fretts 2014 25159901	no	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.	Qt1	% fat intake	0.39	1.33
42	Fretts 2014 25159901	no	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.	Qt2	% fat intake	1.45	1.56
43	Fretts 2014 25159901	no	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.	Qt3	% fat intake	1.65	1.76
44	Fretts 2014 25159901	no	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.	Qt4	% fat intake	1.87	2
45	Fretts 2014 25159901	no	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.	Qt5	% fat intake	2.17	2.44

Row	Study PMID	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
27	Mozaffarian 2013 23546563	nd	HR	nd	nd	nd	0.92	0.71	1.19		
28	Mozaffarian 2013 23546563	nd	HR	nd	nd	nd	1.05	0.82	1.35		
29	Mozaffarian 2013 23546563	nd	HR	nd	nd	nd	0.74	0.56	0.98		
30	Mozaffarian 2013 23546563	nd	HR	nd	nd	nd	0.65	0.48	0.87		
31	Mozaffarian 2013 23546563	nd	HR	nd	nd	nd	Reference group			P trend	0.002
32	Mozaffarian 2013 23546563	nd	HR	nd	nd	nd	1.09	0.84	1.41		
33	Mozaffarian 2013 23546563	nd	HR	nd	nd	nd	1.01	0.78	1.3		
34	Mozaffarian 2013 23546563	nd	HR	nd	nd	nd	0.92	0.7	1.2		
35	Mozaffarian 2013 23546563	nd	HR	nd	nd	nd	0.66	0.49	0.89		
36	Mozaffarian 2013 23546563	nd	HR	nd	nd	nd	Reference group			P trend	0.009
37	Mozaffarian 2013 23546563	nd	HR	nd	nd	nd	1.01	0.79	1.3		
38	Mozaffarian 2013 23546563	nd	HR	nd	nd	nd	0.87	0.67	1.14		
39	Mozaffarian 2013 23546563	nd	HR	nd	nd	nd	0.81	0.62	1.06		
40	Mozaffarian 2013 23546563	nd	HR	nd	nd	nd	0.72	0.54	0.96		
41	Fretts 2014 25159901	1.45	HR	89	nd	4875	Reference group			P trend	0.92
42	Fretts 2014 25159901	1.65	HR	83	nd	4987	0.93	0.68	1.25		
43	Fretts 2014 25159901	1.87	HR	76	nd	5096	0.83	0.61	1.14		
44	Fretts 2014 25159901	2.17	HR	92	nd	5291	0.97	0.72	1.31		
45	Fretts 2014 25159901	4.88	HR	89	nd	5600	0.96	0.71	1.32		

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure
46	Fretts 2014 25159901	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	519/2709 (19.16)	16y	ALA	Plasma
47	Fretts 2014 25159901	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	519/2709 (19.16)	16y	ALA	Plasma
48	Fretts 2014 25159901	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	519/2709 (19.16)	16y	ALA	Plasma
49	Fretts 2014 25159901	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	519/2709 (19.16)	16y	ALA	Plasma
50	Fretts 2014 25159901	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	519/2709 (19.16)	16y	ALA	Plasma
51	Mozaffarian 2013 23546563	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	570/3941 (14.46)	16y	DPA	Plasma
52	Mozaffarian 2013 23546563	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	570/3941 (14.46)	16y	DPA	Plasma
53	Mozaffarian 2013 23546563	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	570/3941 (14.46)	16y	DPA	Plasma
54	Mozaffarian 2013 23546563	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	570/3941 (14.46)	16y	DPA	Plasma
55	Mozaffarian 2013 23546563	Cardiovascular Health Study	CVD death	Total CVD mortality	Healthy	Healthy age >= 65y	All	570/3941 (14.46)	16y	DPA	Plasma
56	Miyagawa 2014 24468152	NIPPON DATA80	CVD death	CHD, Stroke and Heart failure	Healthy	healthy individual with mean age of 50	All	879/9190 (9.56)	24 y	EPA+DHA	Intake
57	Miyagawa 2014 24468152	NIPPON DATA80	CVD death	CHD, Stroke and Heart failure	Healthy	healthy individual with mean age of 50	All	879/9190 (9.56)	24 y	EPA+DHA	Intake
58	Miyagawa 2014 24468152	NIPPON DATA80	CVD death	CHD, Stroke and Heart failure	Healthy	healthy individual with mean age of 50	All	879/9190 (9.56)	24 y	EPA+DHA	Intake
59	Miyagawa 2014 24468152	NIPPON DATA80	CVD death	CHD, Stroke and Heart failure	Healthy	healthy individual with mean age of 50	All	879/9190 (9.56)	24 y	EPA+DHA	Intake
60	Miyagawa 2014 24468152	NIPPON DATA80	CVD death	CHD, Stroke and Heart failure	Healthy	healthy individual with mean age of 50	All	879/9190 (9.56)	24 y	All n-3	Intake
61	Miyagawa 2014 24468152	NIPPON DATA80	CVD death	CHD, Stroke and Heart failure	Healthy	healthy individual with mean age of 50	All	879/9190 (9.56)	24 y	All n-3	Intake
62	Miyagawa 2014 24468152	NIPPON DATA80	CVD death	CHD, Stroke and Heart failure	Healthy	healthy individual with mean age of 50	All	879/9190 (9.56)	24 y	All n-3	Intake
63	Miyagawa 2014 24468152	NIPPON DATA80	CVD death	CHD, Stroke and Heart failure	Healthy	healthy individual with mean age of 50	All	879/9190 (9.56)	24 y	All n-3	Intake
64	Miyagawa 2014 24468152	NIPPON DATA80	CVD death	CHD, Stroke and Heart failure	Healthy	healthy individual with mean age of 50	All	879/9190 (9.56)	24 y	EPA	Intake
65	Miyagawa 2014 24468152	NIPPON DATA80	CVD death	CHD, Stroke and Heart failure	Healthy	healthy individual with mean age of 50	All	879/9190 (9.56)	24 y	EPA	Intake
66	Miyagawa 2014 24468152	NIPPON DATA80	CVD death	CHD, Stroke and Heart failure	Healthy	healthy individual with mean age of 50	All	879/9190 (9.56)	24 y	EPA	Intake
67	Miyagawa 2014 24468152	NIPPON DATA80	CVD death	CHD, Stroke and Heart failure	Healthy	healthy individual with mean age of 50	All	879/9190 (9.56)	24 y	EPA	Intake
68	Miyagawa 2014 24468152	NIPPON DATA80	CVD death	CHD, Stroke and Heart failure	Healthy	healthy individual with mean age of 50	All	879/9190 (9.56)	24 y	DHA	Intake

Row	Study PMID	Supplement	Adjustments	Quantile	n3 units	Quantile low	Quantile median
46	Fretts 2014 25159901	no	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.	Qt1	% FA	0.05	0.09
47	Fretts 2014 25159901	no	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.	Qt2	% FA	0.11	0.12
48	Fretts 2014 25159901	no	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.	Qt3	% FA	0.13	0.14
49	Fretts 2014 25159901	no	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.	Qt4	% FA	0.15	0.17
50	Fretts 2014 25159901	no	age, sex, race, enrolment site, education, smoking status, diabetes, BMI, waist circumference, physical activity, alcohol consumption and treated hypertension.	Qt5	% FA	0.19	0.22
51	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt1	% FA	nd	0.63
52	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt2	% FA	nd	0.75
53	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt3	% FA	nd	0.82
54	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt4	% FA	nd	0.91
55	Mozaffarian 2013 23546563	no	Adjusted for age (years), sex, race (white, nonwhite), education(<high school, high school, some college, college graduate), enrollment site (4 sites), fatty acid measurement batch (1994–96, 2007–10), smoking (never, former, current), prevalent diabetes (yes, no), prevalent atrial fibrillation (yes, no), prevalent drug-treated hypertension (yes, no), leisure-time physical activity (mcal/week), body mass index (kg/m2), waist circumference (cm), and alcohol use (6 categories).	Qt5	% FA	nd	1.04
56	Miyagawa 2014 24468152	no	age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area	Qr1	% kcal	men 0.00, women 0.02	men 0.18, women 0.19
57	Miyagawa 2014 24468152	no	age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area	Qr2	% kcal	men 0.24, women 0.26	men 0.29, women 0.32
58	Miyagawa 2014 24468152	no	age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area	Qr3	% kcal	men 0.36, women 0.39	men 0.43, women 0.46
59	Miyagawa 2014 24468152	no	age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area	Qr4	% kcal	men 0.52, women 0.56	men 0.65, women 0.70
60	Miyagawa 2014 24468152	no	age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area	Qr1	% kcal	men 0.20, women 0.21	nd
61	Miyagawa 2014 24468152	no	age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area	Qr2	% kcal	men 0.86, women 0.94	nd
62	Miyagawa 2014 24468152	no	age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area	Qr3	% kcal	men 1.06, women 1.16	nd
63	Miyagawa 2014 24468152	no	age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area	Qr4	% kcal	men 1.29, women 1.40	nd
64	Miyagawa 2014 24468152	no	age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area	Qr1	% kcal	men 0.00, women 0.00	nd
65	Miyagawa 2014 24468152	no	age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area	Qr2	% kcal	men 0.09, women 0.10	nd
66	Miyagawa 2014 24468152	no	age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area	Qr3	% kcal	men 0.14, women 0.15	nd
67	Miyagawa 2014 24468152	no	age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area	Qr4	% kcal	men 0.20, women 0.22	nd
68	Miyagawa 2014 24468152	no	age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area	Qr1	% kcal	men 0.00, women 0.10	nd

Appendix F Observational results: death from cardiovascular disease

Row	Study PMID	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
46	Fretts 2014 25159901	0.11	HR	101	nd	6483	Reference group			P trend	0.87
47	Fretts 2014 25159901	0.13	HR	108	nd	6025	1.15	0.87	1.53		
48	Fretts 2014 25159901	0.15	HR	102	nd	6315	1.08	0.81	1.44		
49	Fretts 2014 25159901	0.19	HR	102	nd	6352	1.05	0.79	1.4		
50	Fretts 2014 25159901	0.47	HR	106	nd	6936	1.02	0.77	1.36		
51	Mozaffarian 2013 23546563	nd	HR	nd	nd	nd	Reference group			P trend	0.021
52	Mozaffarian 2013 23546563	nd	HR	nd	nd	nd	0.73	0.56	0.95		
53	Mozaffarian 2013 23546563	nd	HR	nd	nd	nd	0.82	0.63	1.06		
54	Mozaffarian 2013 23546563	nd	HR	nd	nd	nd	0.8	0.62	1.03		
55	Mozaffarian 2013 23546563	nd	HR	nd	nd	nd	0.68	0.52	0.89		
56	Miyagawa 2014 24468152	men 0.23, women 0.25	HR	222	nd	47402	1	nd	nd	overal effect for trend	0.144
57	Miyagawa 2014 24468152	men 0.35, women 0.38	HR	210	nd	50196	0.87	0.72	1.05		
58	Miyagawa 2014 24468152	men 0.51, women 0.55	HR	216	nd	47359	0.88	0.73	1.06		
59	Miyagawa 2014 24468152	men 2.34 women 2.43	HR	231	nd	47940	0.85	0.7	1.02		
60	Miyagawa 2014 24468152	men 0.85, women 0.93	HR	281	nd	45771	1	nd	nd	overal effect for trend	0.187
61	Miyagawa 2014 24468152	men 1.05, women 1.15	HR	222	nd	49814	0.95	0.8	1.14		
62	Miyagawa 2014 24468152	men 1.28, women 1.39	HR	179	nd	48876	0.85	0.71	1.03		
63	Miyagawa 2014 24468152	men 3.92 women 3.66	HR	197	nd	48438	0.91	0.76	1.09		
64	Miyagawa 2014 24468152	men 0.08, women 0.09	HR	221	nd	49312	1	nd	nd	overal effect for trend	0.209
65	Miyagawa 2014 24468152	men 0.13, women 0.14	HR	220	nd	49840	0.92	0.76	1.11		
66	Miyagawa 2014 24468152	men 0.19, women 0.21	HR	201	nd	45546	0.88	0.72	1.06		
67	Miyagawa 2014 24468152	men 0.95, women 0.98	HR	237	nd	48200	0.89	0.74	1.07		
68	Miyagawa 2014 24468152	men 0.15, women 0.16	HR	234	nd	49413	1	nd	nd	overal effect for trend	0.099

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure
69	Miyagawa 2014 24468152	NIPPON DATA80	CVD death	CHD, Stroke and Heart failure	Healthy	healthy individual with mean age of 50	All	879/9190 (9.56)	24 y	DHA	Intake
70	Miyagawa 2014 24468152	NIPPON DATA80	CVD death	CHD, Stroke and Heart failure	Healthy	healthy individual with mean age of 50	All	879/9190 (9.56)	24 y	DHA	Intake
71	Miyagawa 2014 24468152	NIPPON DATA80	CVD death	CHD, Stroke and Heart failure	Healthy	healthy individual with mean age of 50	All	879/9190 (9.56)	24 y	DHA	Intake
72	Morris 1995 7598116	Physician's Health Study	CVD death	acute MI, other IHD, sudden death, and other CVD	Healthy	Healthy male physicians	Men	121/21185 (0.57)	4 y	All n-3	Intake
73	Morris 1995 7598116	Physician's Health Study	CVD death	acute MI, other IHD, sudden death, and other CVD	Healthy	Healthy male physicians	Men	121/21185 (0.57)	4 y	All n-3	Intake
74	Morris 1995 7598116	Physician's Health Study	CVD death	acute MI, other IHD, sudden death, and other CVD	Healthy	Healthy male physicians	Men	121/21185 (0.57)	4 y	All n-3	Intake
75	Morris 1995 7598116	Physician's Health Study	CVD death	acute MI, other IHD, sudden death, and other CVD	Healthy	Healthy male physicians	Men	121/21185 (0.57)	4 y	All n-3	Intake
76	Morris 1995 7598116	Physician's Health Study	CVD death	acute MI, other IHD, sudden death, and other CVD	Healthy	Healthy male physicians	Men	121/21185 (0.57)	4 y	All n-3	Intake
77	Nagata 2002 12397000	Takayama	CVD death	death CVD	Healthy	Healthy >35, from Takayama	Men	308/13355 (2.31)	7 y	EPA+DHA	Intake
78	Nagata 2002 12397000	Takayama	CVD death	death CVD	Healthy	Healthy >35, from Takayama	Men	308/13355 (2.31)	7 y	EPA+DHA	Intake
79	Nagata 2002 12397000	Takayama	CVD death	death CVD	Healthy	Healthy >35, from Takayama	Men	308/13355 (2.31)	7 y	EPA+DHA	Intake
80	Nagata 2002 12397000	Takayama	CVD death	death CVD	Healthy	Healthy >35, from Takayama	Men	308/13355 (2.31)	7 y	EPA+DHA	Intake
81	Nagata 2002 12397000	Takayama	CVD death	death CVD	Healthy	Healthy >35, from Takayama	Men	308/13355 (2.31)	7 y	EPA+DHA	Intake
82	Nagata 2002 12397000	Takayama	CVD death	death CVD	Healthy	Healthy >35, from Takayama	Women	327/17125 (1.91)	7 y	EPA+DHA	Intake
83	Nagata 2002 12397000	Takayama	CVD death	death CVD	Healthy	Healthy >35, from Takayama	Women	327/17125 (1.91)	7 y	EPA+DHA	Intake
84	Nagata 2002 12397000	Takayama	CVD death	death CVD	Healthy	Healthy >35, from Takayama	Women	327/17125 (1.91)	7 y	EPA+DHA	Intake
85	Nagata 2002 12397000	Takayama	CVD death	death CVD	Healthy	Healthy >35, from Takayama	Women	327/17125 (1.91)	7 y	EPA+DHA	Intake
86	Nagata 2002 12397000	Takayama	CVD death	death CVD	Healthy	Healthy >35, from Takayama	Women	327/17125 (1.91)	7 y	EPA+DHA	Intake
87	Takata 2013 23788668	Shanghai Women's and Men's Health Studies	CVD death	Ischemic heart disease, stroke, acute MI, other CVD deaths	Healthy	Healthy 40-74	All	5836/134296 (4.35)	11.2 y women; 5.6 y men	EPA	Intake
88	Takata 2013 23788668	Shanghai Women's and Men's Health Studies	CVD death	Ischemic heart disease, stroke, acute MI, other CVD deaths	Healthy	Healthy 40-74	All	5836/134296 (4.35)	11.2 y women; 5.6 y men	EPA	Intake
89	Takata 2013 23788668	Shanghai Women's and Men's Health Studies	CVD death	Ischemic heart disease, stroke, acute MI, other CVD deaths	Healthy	Healthy 40-74	All	5836/134296 (4.35)	11.2 y women; 5.6 y men	EPA	Intake

Row	Study PMID	Supplement	Adjustments	Quantile	n3 units	Quantile low	Quantile median
69	Miyagawa 2014 24468152	no	age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area	Qr2	% kcal	men 0.16, women 0.17	nd
70	Miyagawa 2014 24468152	no	age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area	Qr3	% kcal	men 0.23, women 0.24	nd
71	Miyagawa 2014 24468152	no	age, sex, moking status, drinking status, systolic blood pressure, blood glucose, serum total cholesterol, body mass index, antihypertensive medication status and residential area	Qr4	% kcal	men 0.32, women 0.35	nd
72	Morris 1995 7598116	explicitly excluded fish oil supplements	age, aspirin and beta-carotene assignment, smoking, alcohol consumption, obesity, diabetes, vigorous exercise, parental history of MI before age 60 years, history of hypertension, history of hypercholesterolemia, vitamin supplement use, and saturated fat intake	T1	g/wk	<0.5	nd
73	Morris 1995 7598116	explicitly excluded fish oil supplements	age, aspirin and beta-carotene assignment, smoking, alcohol consumption, obesity, diabetes, vigorous exercise, parental history of MI before age 60 years, history of hypertension, history of hypercholesterolemia, vitamin supplement use, and saturated fat intake	T2	g/wk	0.5	nd
74	Morris 1995 7598116	explicitly excluded fish oil supplements	age, aspirin and beta-carotene assignment, smoking, alcohol consumption, obesity, diabetes, vigorous exercise, parental history of MI before age 60 years, history of hypertension, history of hypercholesterolemia, vitamin supplement use, and saturated fat intake	T3	g/wk	1	nd
75	Morris 1995 7598116	explicitly excluded fish oil supplements	age, aspirin and beta-carotene assignment, smoking, alcohol consumption, obesity, diabetes, vigorous exercise, parental history of MI before age 60 years, history of hypertension, history of hypercholesterolemia, vitamin supplement use, and saturated fat intake	T4	g/wk	1.7	nd
76	Morris 1995 7598116	explicitly excluded fish oil supplements	age, aspirin and beta-carotene assignment, smoking, alcohol consumption, obesity, diabetes, vigorous exercise, parental history of MI before age 60 years, history of hypertension, history of hypercholesterolemia, vitamin supplement use, and saturated fat intake	T5	g/wk	nd	nd
77	Nagata 2002 12397000	No	age, total energy, marital status, BMI, smoking status, alcohol intake, coffee intake, exercise,, and history of hypertension and diabetes	Qt1	mg/d	nd	410
78	Nagata 2002 12397000	No	age, total energy, marital status, BMI, smoking status, alcohol intake, coffee intake, exercise,, and history of hypertension and diabetes	Qt2	mg/d	nd	602
79	Nagata 2002 12397000	No	age, total energy, marital status, BMI, smoking status, alcohol intake, coffee intake, exercise,, and history of hypertension and diabetes	Qt3	mg/d	nd	788
80	Nagata 2002 12397000	No	age, total energy, marital status, BMI, smoking status, alcohol intake, coffee intake, exercise,, and history of hypertension and diabetes	Qt4	mg/d	nd	1051
81	Nagata 2002 12397000	No	age, total energy, marital status, BMI, smoking status, alcohol intake, coffee intake, exercise,, and history of hypertension and diabetes	Qt5	mg/d	nd	1582
82	Nagata 2002 12397000	No	age, total energy, marital status, BMI, smoking status, alcohol intake, coffee intake, exercise, and history of diabetes	Qt1	mg/d	nd	332
83	Nagata 2002 12397000	No	age, total energy, marital status, BMI, smoking status, alcohol intake, coffee intake, exercise, and history of diabetes	Qt2	mg/d	nd	486
84	Nagata 2002 12397000	No	age, total energy, marital status, BMI, smoking status, alcohol intake, coffee intake, exercise, and history of diabetes	Qt3	mg/d	nd	635
85	Nagata 2002 12397000	No	age, total energy, marital status, BMI, smoking status, alcohol intake, coffee intake, exercise, and history of diabetes	Qt4	mg/d	nd	832
86	Nagata 2002 12397000	No	age, total energy, marital status, BMI, smoking status, alcohol intake, coffee intake, exercise, and history of diabetes	Qt5	mg/d	nd	1253
87	Takata 2013 23788668	No	age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only).	Qt1	g/d	nd	0.006 (men), 0.005 (women)
88	Takata 2013 23788668	No	age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only).	Qt2	g/d	nd	0.01 (men), 0.01 (women)
89	Takata 2013 23788668	No	age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only).	Qt3	g/d	nd	0.02 (men), 0.02 (women)

Appendix F Observational results: death from cardiovascular disease

Row	Study PMID	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
69	Miyagawa 2014 24468152	men 0.22, women 0.23	HR	198	nd	46366	0.88	0.73	1.07		
70	Miyagawa 2014 24468152	men 0.31, women 0.34	HR	221	nd	50022	0.86	0.72	1.04		
71	Miyagawa 2014 24468152	men 1.39, women 1.45	HR	226	nd	47097	0.85	0.7	1.02		
72	Morris 1995 7598116	nd	RR	21	4335		1				0.8
73	Morris 1995 7598116	1	RR	27	4134		1.6	0.8	3		
74	Morris 1995 7598116	1.7	RR	31	4691		1.6	0.9	3		
75	Morris 1995 7598116	2.3	RR	17	4075		0.9	0.5	1.9		
76	Morris 1995 7598116	>=2.3	RR	25	3950		1.5	0.8	2.9		
77	Nagata 2002 12397000	nd	HR	60	nd	18281	Reference group			P trend	0.27
78	Nagata 2002 12397000	nd	HR	53	nd	18315	0.74	0.51	1.08		
79	Nagata 2002 12397000	nd	HR	53	nd	18186	0.71	0.49	1.03		
80	Nagata 2002 12397000	nd	HR	71	nd	18138	0.82	0.58	1.15		
81	Nagata 2002 12397000	nd	HR	71	nd	18116	0.76	0.54	1.07		
82	Nagata 2002 12397000	nd	HR	85	nd	21838	Reference group			P trend	0.16
83	Nagata 2002 12397000	nd	HR	60	nd	22111	0.82	0.59	1.15		
84	Nagata 2002 12397000	nd	HR	57	nd	22032	0.79	0.58	1.11		
85	Nagata 2002 12397000	nd	HR	64	nd	22025	0.86	0.62	1.2		
86	Nagata 2002 12397000	nd	HR	61	nd	22118	0.77	0.55	1		
87	Takata 2013 23788668	nd	HR	715	26860	nd	Reference group			P trend	0.03
88	Takata 2013 23788668	nd	HR	362	nd	nd	0.81	0.71	0.92		
89	Takata 2013 23788668	nd	HR	290	26860	nd	0.83	0.72	0.96		

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure
90	Takata 2013 23788668	Shanghai Women's and Men's Health Studies	CVD death	Ischemic heart disease, stroke, acute MI, other CVD deaths	Healthy	Healthy 40-74	All	5836/134296 (4.35)	11.2 y women; 5.6 y men	EPA	Intake
91	Takata 2013 23788668	Shanghai Women's and Men's Health Studies	CVD death	Ischemic heart disease, stroke, acute MI, other CVD deaths	Healthy	Healthy 40-74	All	5836/134296 (4.35)	11.2 y women; 5.6 y men	EPA	Intake
92	Takata 2013 23788668	Shanghai Women's and Men's Health Studies	CVD death	Ischemic heart disease, stroke, acute MI, other CVD deaths	Healthy	Healthy 40-74	All	5836/134296 (4.35)	11.2 y women; 5.6 y men	DHA	Intake
93	Takata 2013 23788668	Shanghai Women's and Men's Health Studies	CVD death	Ischemic heart disease, stroke, acute MI, other CVD deaths	Healthy	Healthy 40-74	All	5836/134296 (4.35)	11.2 y women; 5.6 y men	DHA	Intake
94	Takata 2013 23788668	Shanghai Women's and Men's Health Studies	CVD death	Ischemic heart disease, stroke, acute MI, other CVD deaths	Healthy	Healthy 40-74	All	5836/134296 (4.35)	11.2 y women; 5.6 y men	DHA	Intake
95	Takata 2013 23788668	Shanghai Women's and Men's Health Studies	CVD death	Ischemic heart disease, stroke, acute MI, other CVD deaths	Healthy	Healthy 40-74	All	5836/134296 (4.35)	11.2 y women; 5.6 y men	DHA	Intake
96	Takata 2013 23788668	Shanghai Women's and Men's Health Studies	CVD death	Ischemic heart disease, stroke, acute MI, other CVD deaths	Healthy	Healthy 40-74	All	5836/134296 (4.35)	11.2 y women; 5.6 y men	DHA	Intake
97	Takata 2013 23788668	Shanghai Women's and Men's Health Studies	CVD death	Ischemic heart disease, stroke, acute MI, other CVD deaths	Healthy	Healthy 40-74	All	5836/134296 (4.35)	11.2 y women; 5.6 y men	EPA+DHA	Intake
98	Takata 2013 23788668	Shanghai Women's and Men's Health Studies	CVD death	Ischemic heart disease, stroke, acute MI, other CVD deaths	Healthy	Healthy 40-74	All	5836/134296 (4.35)	11.2 y women; 5.6 y men	EPA+DHA	Intake
99	Takata 2013 23788668	Shanghai Women's and Men's Health Studies	CVD death	Ischemic heart disease, stroke, acute MI, other CVD deaths	Healthy	Healthy 40-74	All	5836/134296 (4.35)	11.2 y women; 5.6 y men	EPA+DHA	Intake
100	Takata 2013 23788668	Shanghai Women's and Men's Health Studies	CVD death	Ischemic heart disease, stroke, acute MI, other CVD deaths	Healthy	Healthy 40-74	All	5836/134296 (4.35)	11.2 y women; 5.6 y men	EPA+DHA	Intake
101	Takata 2013 23788668	Shanghai Women's and Men's Health Studies	CVD death	Ischemic heart disease, stroke, acute MI, other CVD deaths	Healthy	Healthy 40-74	All	5836/134296 (4.35)	11.2 y women; 5.6 y men	EPA+DHA	Intake
102	Warensjo 2008 18614742	ULSAM	CVD death	Cardiovascular disease mortality	Healthy	Healthy	All	461/2009 (22.95)	30.7	ALA	Plasma
103	Warensjo 2008 18614742	ULSAM	CVD death	Cardiovascular disease mortality	Healthy	Healthy	All	461/2009 (19.0/ 1000 person-yrs)	30.7	EPA	Plasma
104	Warensjo 2008 18614742	ULSAM	CVD death	Cardiovascular disease mortality	Healthy	Healthy	All	461/2009 (19.0/ 1000 person-yrs)	30.7	DHA	Plasma
105	Yamagishi 2008 18786479	JACC	CVD death	Total CVD mortality	Healthy	Healthy 40-79 yo	All	2045/57972 (3.53)	12.7 y	All n-3	Intake
106	Yamagishi 2008 18786479	JACC	CVD death	Total CVD mortality	Healthy	Healthy 40-79 yo	All	2045/57972 (3.53)	12.7 y	All n-3	Intake
107	Yamagishi 2008 18786479	JACC	CVD death	Total CVD mortality	Healthy	Healthy 40-79 yo	All	2045/57972 (3.53)	12.7 y	All n-3	Intake
108	Yamagishi 2008 18786479	JACC	CVD death	Total CVD mortality	Healthy	Healthy 40-79 yo	All	2045/57972 (3.53)	12.7 y	All n-3	Intake
109	Yamagishi 2008 18786479	JACC	CVD death	Total CVD mortality	Healthy	Healthy 40-79 yo	All	2045/57972 (3.53)	12.7 y	All n-3	Intake

Row	Study PMID	Supplement	Adjustments	Quantile	n3 units	Quantile low	Quantile median
90	Takata 2013 23788668	No	age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only).	Qt4	g/d	nd	0.03 (men), 0.03 (women)
91	Takata 2013 23788668	No	age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only).	Qt5	g/d	nd	0.07 (men), 0.06 (women)
92	Takata 2013 23788668	No	age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only).	Qt1	g/d	nd	0.009 (men), 0.008 (women)
93	Takata 2013 23788668	No	age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only).	Qt2	g/d	nd	0.02 (men), 0.02 (women)
94	Takata 2013 23788668	No	age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only).	Qt3	g/d	nd	0.05 (men), 0.04 (women)
95	Takata 2013 23788668	No	age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only).	Qt4	g/d	nd	0.08 (men), 0.08 (women)
96	Takata 2013 23788668	No	age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only).	Qt5	g/d	nd	0.15 (men), 0.15 (women)
97	Takata 2013 23788668	No	age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only).	Qt1	g/d	nd	nd
98	Takata 2013 23788668	No	age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only).	Qt2	g/d	nd	nd
99	Takata 2013 23788668	No	age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only).	Qt3	g/d	nd	nd
100	Takata 2013 23788668	No	age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only).	Qt4	g/d	nd	nd
101	Takata 2013 23788668	No	age at baseline, total energy intake, income, occupation, education, comorbidity index, physical activity level, red meat intake, poultry intake, total vegetable intake, total fruit intake, smoking history (ever/never smoking for women; pack-years of smoking for men), and alcohol consumption (among men only).	Qt5	g/d	nd	nd
102	Warensjo 2008 18614742	NA	total cholestrol, BMI, smoking, physical activity, hypertension	All	% FA	nd	0.66 (SD = 0.16)
103	Warensjo 2008 18614742	NA	total cholestrol, BMI, smoking, physical activity, hypertension	All	% FA	0.9	1.3
104	Warensjo 2008 18614742	NA	total cholestrol, BMI, smoking, physical activity, hypertension	All	% FA	0.56	0.68
105	Yamagishi 2008 18786479	No	age, sex, htn and dm history, smoking status, alcohol consumption, BMI, mental stress, walking, sports, education, total energy, dietary intake of cholesterol/saturated and omega-3FA/vegetables/fruit	Qt1	g/d	0.05	nd
106	Yamagishi 2008 18786479	No	age, sex, htn and dm history, smoking status, alcohol consumption, BMI, mental stress, walking, sports, education, total energy, dietary intake of cholesterol/saturated and omega-3FA/vegetables/fruit	Qt2	g/d	1.18	nd
107	Yamagishi 2008 18786479	No	age, sex, htn and dm history, smoking status, alcohol consumption, BMI, mental stress, walking, sports, education, total energy, dietary intake of cholesterol/saturated and omega-3FA/vegetables/fruit	Qt3	g/d	1.47	nd
108	Yamagishi 2008 18786479	No	age, sex, htn and dm history, smoking status, alcohol consumption, BMI, mental stress, walking, sports, education, total energy, dietary intake of cholesterol/saturated and omega-3FA/vegetables/fruit	Qt4	g/d	1.75	nd
109	Yamagishi 2008 18786479	No	age, sex, htn and dm history, smoking status, alcohol consumption, BMI, mental stress, walking, sports, education, total energy, dietary intake of cholesterol/saturated and omega-3FA/vegetables/fruit	Qt5	g/d	2.11	nd

Row	Study PMID	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
90	Takata 2013 23788668	nd	HR	232	nd	nd	0.83	0.7	0.97		
91	Takata 2013 23788668	nd	HR	190	26858	nd	0.75	0.62	0.89		
92	Takata 2013 23788668	nd	HR	707	26860	nd	Reference group			P trend	0.01
93	Takata 2013 23788668	nd	HR	359	nd	nd	0.81	0.71	0.92		
94	Takata 2013 23788668	nd	HR	272	26860	nd	0.78	0.67	0.9		
95	Takata 2013 23788668	nd	HR	260	nd	nd	0.89	0.76	1.03		
96	Takata 2013 23788668	nd	HR	193	26858	nd	0.76	0.63	0.9		
97	Takata 2013 23788668	nd	HR	714	26860	nd	Reference group			P trend	0.02
98	Takata 2013 23788668	nd	HR	356	nd	nd	0.82	0.63	1.08		
99	Takata 2013 23788668	nd	HR	271	26860	nd	0.78	0.67	0.9		
100	Takata 2013 23788668	nd	HR	258	nd	nd	0.9	0.77	1.05		
101	Takata 2013 23788668	nd	HR	190	26858	nd	0.74	0.62	0.88		
102	Warensjo 2008 18614742	nd	HR	nd	nd	nd	1.1	1	1.21	Per % FA unit	
103	Warensjo 2008 18614742	1.6	HR	nd	nd	nd	0.99	0.9	1.09	Per % FA unit	
104	Warensjo 2008 18614742	0.81	HR	nd	nd	nd	0.92	0.84	1.02	Per % FA unit	
105	Yamagishi 2008 18786479	1.18	HR	360	11594	735904	Reference group				0.01
106	Yamagishi 2008 18786479	1.47	HR	367	11595	735904	0.93	0.8	1.09		
107	Yamagishi 2008 18786479	1.75	HR	412	11594	735904	0.91	0.78	1.07		
108	Yamagishi 2008 18786479	2.11	HR	388	11595	735904	0.81	0.68	0.96		
109	Yamagishi 2008 18786479	5.06	HR	518	11594	735904	0.81	0.67	0.98		

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure
110	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		All	4780/60298 (0.79)	5 y	All n-3	Intake
111	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		All	4780/60298 (0.79)	5 y	All n-3	Intake
112	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		All	4780/60298 (0.79)	5 y	All n-3	Intake
113	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		All	4780/60298 (0.79)	5 y	All n-3	Intake
114	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		All	4780/60298 (0.79)	5 y	EPA + DHA	Intake
115	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		All	4780/60298 (0.79)	5 y	EPA + DHA	Intake
116	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		All	4780/60298 (0.79)	5 y	EPA + DHA	Intake
117	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		All	4780/60298 (0.79)	5 y	EPA + DHA	Intake
118	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		All	4780/60298 (0.79)	5 y	ALA	Intake
119	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		All	4780/60298 (0.79)	5 y	ALA	Intake
120	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		All	4780/60298 (0.79)	5 y	ALA	Intake
121	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		All	4780/60298 (0.79)	5 y	ALA	Intake
123	Subgroup analyses										
124	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		CVD		prior history of CHD or stroke	nd/860	5 y	All n-3	intake
125	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		CVD		prior history of CHD or stroke	nd/860	5 y	All n-3	intake
126	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		CVD		prior history of CHD or stroke	nd/860	5 y	All n-3	intake
127	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		CVD		prior history of CHD or stroke	nd/860	5 y	All n-3	intake

Row	Study PMID	Supplement	Adjustments	Quantile	n3 units	Quantile low	Quantile median
110	Koh_2013_24343844	No	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr1	nd	nd	nd
111	Koh_2013_24343844	No	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr2	nd	nd	nd
112	Koh_2013_24343844	No	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr3	nd	nd	nd
113	Koh_2013_24343844	No	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr4	nd	nd	nd
114	Koh_2013_24343844	No	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr1	nd	nd	nd
115	Koh_2013_24343844	No	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr2	nd	nd	nd
116	Koh_2013_24343844	No	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr3	nd	nd	nd
117	Koh_2013_24343844	No	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr4	nd	nd	nd
118	Koh_2013_24343844	No	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr1	nd	nd	nd
119	Koh_2013_24343844	No	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr2	nd	nd	nd
120	Koh_2013_24343844	No	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr3	nd	nd	nd
121	Koh_2013_24343844	No	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr4	nd	nd	nd
123	Subgroup analyses						
124	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr1	nd	nd	nd
125	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr2	nd	nd	nd
126	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr3	nd	nd	nd
127	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr4	nd	nd	nd

Appendix F Observational results: death from cardiovascular disease

Row	Study PMID	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
110	Koh_2013_24343844	nd	HR	1329	15181	nd	Ref			P trend	0.003
111	Koh_2013_24343844	nd	HR	1200	15022	nd	0.88	0.81	0.96		
112	Koh_2013_24343844	nd	HR	1196	15023	nd	0.88	0.8	0.97		
113	Koh_2013_24343844	nd	HR	1055	15072	nd	0.83	0.74	0.92		
114	Koh_2013_24343844	nd	HR	1236	15181	nd	Ref			P trend	0.004
115	Koh_2013_24343844	nd	HR	1233	15022	nd	0.96	0.89	1.05		
116	Koh_2013_24343844	nd	HR	1188	15023	nd	0.9	0.82	0.99		
117	Koh_2013_24343844	nd	HR	1123	15072	nd	0.86	0.77	0.96		
118	Koh_2013_24343844	nd	HR	1342	15181	nd	Ref			P trend	<0.001
119	Koh_2013_24343844	nd	HR	1267	15022	nd	0.94	0.86	1.02		
120	Koh_2013_24343844	nd	HR	1156	15023	nd	0.87	0.79	0.95		
121	Koh_2013_24343844	nd	HR	1015	15072	nd	0.81	0.73	0.9		
123	Subgroup analyses										
124	Koh_2013_24343844	nd	HR	206	nd		Ref			P trend	0.35
125	Koh_2013_24343844	nd	HR	204	nd		0.84	0.68	1.04		
126	Koh_2013_24343844	nd	HR	222	nd		0.9	0.71	1.14		
127	Koh_2013_24343844	nd	HR	228	nd		0.85	0.66	1.1		

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure
128	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		CVD		prior history of CHD or stroke	nd/860	5 y	EPA + DHA	intake
129	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		CVD		prior history of CHD or stroke	nd/860	5 y	EPA + DHA	intake
130	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		CVD		prior history of CHD or stroke	nd/860	5 y	EPA + DHA	intake
131	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		CVD		prior history of CHD or stroke	nd/860	5 y	EPA + DHA	intake
132	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		CVD		prior history of CHD or stroke	nd/860	5 y	ALA	intake
133	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		CVD		prior history of CHD or stroke	nd/860	5 y	ALA	intake
134	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		CVD		prior history of CHD or stroke	nd/860	5 y	ALA	intake
135	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		CVD		prior history of CHD or stroke	nd/860	5 y	ALA	intake
136	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		no prior history of CHD or stroke	nd/3920	5 y	All n-3	intake
137	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		no prior history of CHD or stroke	nd/3920	5 y	All n-3	intake
138	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		no prior history of CHD or stroke	nd/3920	5 y	All n-3	intake
139	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		no prior history of CHD or stroke	nd/3920	5 y	All n-3	intake
140	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		no prior history of CHD or stroke	nd/3920	5 y	EPA + DHA	intake
141	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		no prior history of CHD or stroke	nd/3920	5 y	EPA + DHA	intake
142	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		no prior history of CHD or stroke	nd/3920	5 y	EPA + DHA	intake
143	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		no prior history of CHD or stroke	nd/3920	5 y	EPA + DHA	intake
144	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		no prior history of CHD or stroke	nd/3920	5 y	ALA	intake

Row	Study PMID	Supplement	Adjustments	Quantile	n3 units	Quantile low	Quantile median
128	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr1	nd	nd	nd
129	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr2	nd	nd	nd
130	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr3	nd	nd	nd
131	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr4	nd	nd	nd
132	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr1	nd	nd	nd
133	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr2	nd	nd	nd
134	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr3	nd	nd	nd
135	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr4	nd	nd	nd
136	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr1	nd	nd	nd
137	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr2	nd	nd	nd
138	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr3	nd	nd	nd
139	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr4	nd	nd	nd
140	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr1	nd	nd	nd
141	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr2	nd	nd	nd
142	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr3	nd	nd	nd
143	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr4	nd	nd	nd
144	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr1	nd	nd	nd

Appendix F Observational results: death from cardiovascular disease

Row	Study PMID	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
128	Koh_2013_24343844	nd	HR	197	nd		Ref			P trend	0.47
129	Koh_2013_24343844	nd	HR	212	nd		1	0.81	1.22		
130	Koh_2013_24343844	nd	HR	241	nd		1.03	0.83	1.29		
131	Koh_2013_24343844	nd	HR	210	nd		0.92	0.71	1.19		
132	Koh_2013_24343844	nd	HR	212	nd		Ref			P trend	0.14
133	Koh_2013_24343844	nd	HR	234	nd		1.08	0.88	1.32		
134	Koh_2013_24343844	nd	HR	190	nd		0.85	0.68	1.06		
135	Koh_2013_24343844	nd	HR	224	nd		0.87	0.69	1.1		
136	Koh_2013_24343844	nd	HR	1123	nd		Ref			P trend	0.006
137	Koh_2013_24343844	nd	HR	996	nd		0.89	0.81	0.98		
138	Koh_2013_24343844	nd	HR	974	nd		0.88	0.79	0.98		
139	Koh_2013_24343844	nd	HR	827	nd		0.83	0.73	0.94		
140	Koh_2013_24343844	nd	HR	1039	nd		Ref			P trend	0.002
141	Koh_2013_24343844	nd	HR	1021	nd		0.94	0.86	1.03		
142	Koh_2013_24343844	nd	HR	947	nd		0.87	0.79	0.96		
143	Koh_2013_24343844	nd	HR	913	nd		0.84	0.74	0.95		
144	Koh_2013_24343844	nd	HR	1130	nd		Ref			P trend	<0.001

Appendix F Observational results: death from cardiovascular disease

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure
145	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		no prior history of CHD or stroke	nd/3920	5 y	ALA	intake
146	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		no prior history of CHD or stroke	nd/3920	5 y	ALA	intake
147	Koh_2013_24343844	The Singapore Chinese Health Study	CVD death		Healthy		no prior history of CHD or stroke	nd/3920	5 y	ALA	intake
148	Bell 2014 24496442	VITAL	CVD death		Healthy	Men and women aged 50-76	History of CVD at baseline	nd/362	6 y	EPA+DHA	Intake
149	Bell 2014 24496442	VITAL	CVD death		Healthy	Men and women aged 50-76	History of CVD at baseline	nd/362	6 y	EPA+DHA	Intake
150	Bell 2014 24496442	VITAL	CVD death		Healthy	Men and women aged 50-76	History of CVD at baseline	nd/362	6 y	EPA+DHA	Intake
151	Bell 2014 24496442	VITAL	CVD death		Healthy	Men and women aged 50-76	History of CVD at baseline	nd/362	6 y	EPA+DHA	Intake

Row	Study PMID	Supplement	Adjustments	Quantile	n3 units	Quantile low	Quantile median
145	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr2	nd	nd	nd
146	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr3	nd	nd	nd
147	Koh_2013_24343844	no	age, sex, dialect, year of interview, educational level, body mass index, physical activity, smoking status, alcohol use, baseline history of self-reported diabetes, hypertension, coronary heart disease, stroke, intakes of total energy, protein, dietary fibre, saturated fat, monounsaturated fat, omega-6 fatty acids, and alternate omega-3 fatty acids (in the analysis of EPA/DHA or ALA)	Qr4	nd	nd	nd
148	Bell 2014 24496442	yes	age (as the time scale), sex, race/ethnicity, marital status (married/living together, never married, separated/divorced, widowed, or missing), education (high school graduate or less, some college, or college/advanced degree), total energy intake (kcal/day; continuous), body mass index (weight (kg)/height (m)2 (none, <1 drink/day, 1–2 drinks/day, >2 drinks/day, or missing), average physical activity in the 10 years before baseline (MET-hours/week; tertiles), self-rated health (excellent, very good, good, fair, or poor), mammogram in the last 2 years (yes/no), prostate-specific antigen test in the last 2 years (yes/no), sigmoidoscopy in the last 10 years (yes/no), current use of cholesterol-lowering medication (yes/no), aspirin use in the past 10 years (none, low, high, or missing), use of nonaspirin nonsteroidal antiinflammatory drugs in the past 10 years (none, low, high, or missing), smoking (never, 1–12.5 pack-years, 12.6–35.0 pack-years, or >35.0 pack-years), morbidity score,c percentage of calories derived from trans fat (quartiles), percentage of calories derived from saturated fat (quartiles), number of servings per day of fruits (quartiles), number of servings per day of vegetables (quartiles), years of estrogen therapy (none, <5, 5–9, ≥10, or missing), years of estrogen + progestin therapy (none, <5, 5–9, ≥10, or missing), age at menopause (≤39 years, 40–44 years, 45–49 years, 50–54 years, ≥55 years, or missing), age at death of father (≤59 years, 60–69 years, 70–79 years, 80–89 years, or ≥90 years), and age at death of mother (≤59 years, 60–69 years, 70–79 years, 80–89 years, or ≥90 years)	Qr1	g/day	0	nd
149	Bell 2014 24496442	yes	age (as the time scale), sex, race/ethnicity, marital status (married/living together, never married, separated/divorced, widowed, or missing), education (high school graduate or less, some college, or college/advanced degree), total energy intake (kcal/day; continuous), body mass index (weight (kg)/height (m)2 (none, <1 drink/day, 1–2 drinks/day, >2 drinks/day, or missing), average physical activity in the 10 years before baseline (MET-hours/week; tertiles), self-rated health (excellent, very good, good, fair, or poor), mammogram in the last 2 years (yes/no), prostate-specific antigen test in the last 2 years (yes/no), sigmoidoscopy in the last 10 years (yes/no), current use of cholesterol-lowering medication (yes/no), aspirin use in the past 10 years (none, low, high, or missing), use of nonaspirin nonsteroidal antiinflammatory drugs in the past 10 years (none, low, high, or missing), smoking (never, 1–12.5 pack-years, 12.6–35.0 pack-years, or >35.0 pack-years), morbidity score,c percentage of calories derived from trans fat (quartiles), percentage of calories derived from saturated fat (quartiles), number of servings per day of fruits (quartiles), number of servings per day of vegetables (quartiles), years of estrogen therapy (none, <5, 5–9, ≥10, or missing), years of estrogen + progestin therapy (none, <5, 5–9, ≥10, or missing), age at menopause (≤39 years, 40–44 years, 45–49 years, 50–54 years, ≥55 years, or missing), age at death of father (≤59 years, 60–69 years, 70–79 years, 80–89 years, or ≥90 years), and age at death of mother (≤59 years, 60–69 years, 70–79 years, 80–89 years, or ≥90 years)	Qr2	g/day	0.082	nd
150	Bell 2014 24496442	yes	age (as the time scale), sex, race/ethnicity, marital status (married/living together, never married, separated/divorced, widowed, or missing), education (high school graduate or less, some college, or college/advanced degree), total energy intake (kcal/day; continuous), body mass index (weight (kg)/height (m)2 (none, <1 drink/day, 1–2 drinks/day, >2 drinks/day, or missing), average physical activity in the 10 years before baseline (MET-hours/week; tertiles), self-rated health (excellent, very good, good, fair, or poor), mammogram in the last 2 years (yes/no), prostate-specific antigen test in the last 2 years (yes/no), sigmoidoscopy in the last 10 years (yes/no), current use of cholesterol-lowering medication (yes/no), aspirin use in the past 10 years (none, low, high, or missing), use of nonaspirin nonsteroidal antiinflammatory drugs in the past 10 years (none, low, high, or missing), smoking (never, 1–12.5 pack-years, 12.6–35.0 pack-years, or >35.0 pack-years), morbidity score,c percentage of calories derived from trans fat (quartiles), percentage of calories derived from saturated fat (quartiles), number of servings per day of fruits (quartiles), number of servings per day of vegetables (quartiles), years of estrogen therapy (none, <5, 5–9, ≥10, or missing), years of estrogen + progestin therapy (none, <5, 5–9, ≥10, or missing), age at menopause (≤39 years, 40–44 years, 45–49 years, 50–54 years, ≥55 years, or missing), age at death of father (≤59 years, 60–69 years, 70–79 years, 80–89 years, or ≥90 years), and age at death of mother (≤59 years, 60–69 years, 70–79 years, 80–89 years, or ≥90 years)	Qr3	g/day	0.174	nd
151	Bell 2014 24496442	yes		Qr4	g/day	0.322	nd

Appendix F Observational results: death from cardiovascular disease

Row	Study PMID	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
145	Koh_2013_24343844	nd	HR	1033	nd		0.91	0.83	1		
146	Koh_2013_24343844	nd	HR	966	nd		0.89	0.8	0.98		
147	Koh_2013_24343844	nd	HR	791	nd		0.81	0.72	0.9		
148	Bell 2014 24496442	0.082	HR	98	nd	nd	1	nd	nd		0.167
149	Bell 2014 24496442	0.174	HR	91	nd	nd	1.01	0.74	1.37		
150	Bell 2014 24496442	0.322	HR	80	nd	nd	0.81	0.58	1.14		
151	Bell 2014 24496442	nd	HR	93	nd	nd	0.82	0.57	1.17		

Appendix F Observational results: death from cardiovascular disease

Row	Study PMID	Study Name	Outcome	Outcome Definition	Population Type	Population	Subgroup	Cases Total/N Total (Rate %)	Followup	n3 FA	n3 measure
152	Bell 2014 24496442	VITAL	CVD death		Healthy	Men and women aged 50-76	No history of CVD at baseline	nd/400	6 y	EPA+DHA	Intake
153	Bell 2014 24496442	VITAL	CVD death		Healthy	Men and women aged 50-76	No history of CVD at baseline	nd/400	6 y	EPA+DHA	Intake
154	Bell 2014 24496442	VITAL	CVD death		Healthy	Men and women aged 50-76	No history of CVD at baseline	nd/400	6 y	EPA+DHA	Intake
155	Bell 2014 24496442	VITAL	CVD death		Healthy	Men and women aged 50-76	No history of CVD at baseline	nd/400	6 y	EPA+DHA	Intake

Row	Study PMID	Supplement	Adjustments	Quantile	n3 units	Quantile low	Quantile median
152	Bell 2014 24496442	yes	age (as the time scale), sex, race/ethnicity, marital status (married/living together, never married, separated/divorced, widowed, or missing), education (high school graduate or less, some college, or college/advanced degree), total energy intake (kcal/day; continuous), body mass index (weight (kg)/height (m)2 (none, <1 drink/day, 1–2 drinks/day, >2 drinks/day, or missing), average physical activity in the 10 years before baseline (MET-hours/week; tertiles), self-rated health (excellent, very good, good, fair, or poor), mammogram in the last 2 years (yes/no), prostate-specific antigen test in the last 2 years (yes/no), sigmoidoscopy in the last 10 years (yes/no), current use of cholesterol-lowering medication (yes/no), aspirin use in the past 10 years (none, low, high, or missing), use of nonaspirin nonsteroidal antiinflammatory drugs in the past 10 years (none, low, high, or missing), smoking (never, 1–12.5 pack-years, 12.6–35.0 pack-years, or >35.0 pack-years), morbidity score,c percentage of calories derived from trans fat (quartiles), percentage of calories derived from saturated fat (quartiles), number of servings per day of fruits (quartiles), number of servings per day of vegetables (quartiles), years of estrogen therapy (none, <5, 5–9, ≥10, or missing), years of estrogen + progestin therapy (none, <5, 5–9, ≥10, or missing), age at menopause (≤39 years, 40–44 years, 45–49 years, 50–54 years, ≥55 years, or missing), age at death of father (≤59 years, 60–69 years, 70–79 years, 80–89 years, or ≥90 years), and age at death of mother (≤59 years, 60–69 years, 70–79 years, 80–89 years, or ≥90 years)	Qr1	g/day	0	nd
153	Bell 2014 24496442	yes	age (as the time scale), sex, race/ethnicity, marital status (married/living together, never married, separated/divorced, widowed, or missing), education (high school graduate or less, some college, or college/advanced degree), total energy intake (kcal/day; continuous), body mass index (weight (kg)/height (m)2 (none, <1 drink/day, 1–2 drinks/day, >2 drinks/day, or missing), average physical activity in the 10 years before baseline (MET-hours/week; tertiles), self-rated health (excellent, very good, good, fair, or poor), mammogram in the last 2 years (yes/no), prostate-specific antigen test in the last 2 years (yes/no), sigmoidoscopy in the last 10 years (yes/no), current use of cholesterol-lowering medication (yes/no), aspirin use in the past 10 years (none, low, high, or missing), use of nonaspirin nonsteroidal antiinflammatory drugs in the past 10 years (none, low, high, or missing), smoking (never, 1–12.5 pack-years, 12.6–35.0 pack-years, or >35.0 pack-years), morbidity score,c percentage of calories derived from trans fat (quartiles), percentage of calories derived from saturated fat (quartiles), number of servings per day of fruits (quartiles), number of servings per day of vegetables (quartiles), years of estrogen therapy (none, <5, 5–9, ≥10, or missing), years of estrogen + progestin therapy (none, <5, 5–9, ≥10, or missing), age at menopause (≤39 years, 40–44 years, 45–49 years, 50–54 years, ≥55 years, or missing), age at death of father (≤59 years, 60–69 years, 70–79 years, 80–89 years, or ≥90 years), and age at death of mother (≤59 years, 60–69 years, 70–79 years, 80–89 years, or ≥90 years)	Qr2	g/day	0.082	nd
154	Bell 2014 24496442	yes	age (as the time scale), sex, race/ethnicity, marital status (married/living together, never married, separated/divorced, widowed, or missing), education (high school graduate or less, some college, or college/advanced degree), total energy intake (kcal/day; continuous), body mass index (weight (kg)/height (m)2 (none, <1 drink/day, 1–2 drinks/day, >2 drinks/day, or missing), average physical activity in the 10 years before baseline (MET-hours/week; tertiles), self-rated health (excellent, very good, good, fair, or poor), mammogram in the last 2 years (yes/no), prostate-specific antigen test in the last 2 years (yes/no), sigmoidoscopy in the last 10 years (yes/no), current use of cholesterol-lowering medication (yes/no), aspirin use in the past 10 years (none, low, high, or missing), use of nonaspirin nonsteroidal antiinflammatory drugs in the past 10 years (none, low, high, or missing), smoking (never, 1–12.5 pack-years, 12.6–35.0 pack-years, or >35.0 pack-years), morbidity score,c percentage of calories derived from trans fat (quartiles), percentage of calories derived from saturated fat (quartiles), number of servings per day of fruits (quartiles), number of servings per day of vegetables (quartiles), years of estrogen therapy (none, <5, 5–9, ≥10, or missing), years of estrogen + progestin therapy (none, <5, 5–9, ≥10, or missing), age at menopause (≤39 years, 40–44 years, 45–49 years, 50–54 years, ≥55 years, or missing), age at death of father (≤59 years, 60–69 years, 70–79 years, 80–89 years, or ≥90 years), and age at death of mother (≤59 years, 60–69 years, 70–79 years, 80–89 years, or ≥90 years)	Qr3	g/day	0.174	nd
155	Bell 2014 24496442	yes	age (as the time scale), sex, race/ethnicity, marital status (married/living together, never married, separated/divorced, widowed, or missing), education (high school graduate or less, some college, or college/advanced degree), total energy intake (kcal/day; continuous), body mass index (weight (kg)/height (m)2 (none, <1 drink/day, 1–2 drinks/day, >2 drinks/day, or missing), average physical activity in the 10 years before baseline (MET-hours/week; tertiles), self-rated health (excellent, very good, good, fair, or poor), mammogram in the last 2 years (yes/no), prostate-specific antigen test in the last 2 years (yes/no), sigmoidoscopy in the last 10 years (yes/no), current use of cholesterol-lowering medication (yes/no), aspirin use in the past 10 years (none, low, high, or missing), use of nonaspirin nonsteroidal antiinflammatory drugs in the past 10 years (none, low, high, or missing), smoking (never, 1–12.5 pack-years, 12.6–35.0 pack-years, or >35.0 pack-years), morbidity score,c percentage of calories derived from trans fat (quartiles), percentage of calories derived from saturated fat (quartiles), number of servings per day of fruits (quartiles), number of servings per day of vegetables (quartiles), years of estrogen therapy (none, <5, 5–9, ≥10, or missing), years of estrogen + progestin therapy (none, <5, 5–9, ≥10, or missing), age at menopause (≤39 years, 40–44 years, 45–49 years, 50–54 years, ≥55 years, or missing), age at death of father (≤59 years, 60–69 years, 70–79 years, 80–89 years, or ≥90 years), and age at death of mother (≤59 years, 60–69 years, 70–79 years, 80–89 years, or ≥90 years)	Qr4	g/day	0.322	nd

Appendix F Observational results: death from cardiovascular disease

Row	Study PMID	Quantile high	Metric	n Cases	N quantile	Person Years	Estimate	CI low	CI high	Comparison	P value
152	Bell 2014 24496442	0.082	HR	129	nd	nd	1	nd	nd		0.799
153	Bell 2014 24496442	0.174	HR	92	nd	nd	0.77	0.58	1.02		
154	Bell 2014 24496442	0.322	HR	84	nd	nd	0.78	0.57	1.05		
155	Bell 2014 24496442	nd	HR	95	nd	nd	0.91	0.66	1.27		